Appointment of Internal Auditor.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma Ltd reported FY2026 revenue of Rs. 77,166 lakhs, up 16.6% from Rs. 66,151 lakhs in FY2025. However, profit after tax declined 13.3% to Rs. 4,105 lakhs from Rs. 4,735 lakhs. EBITDA margin compressed to 8.56% from 10.64% in the prior year. The Board recommended a dividend of Rs. 1.50 per share (30% payout). Statutory auditors Jayantilal Thakkar & Co. issued an unmodified opinion. Key appointments include M/s. RMJ & Associates LLP as Internal Auditors for FY2026-27 and Ankit Kishor Chande as Cost Auditor. Nine promoter group members holding 0.95% shareholding have requested reclassification to public category. The 66th AGM is scheduled for 12th August 2026.
Revenue growth was offset by margin compression and PAT decline, which may concern investors focused on profitability. The dividend payout and clean audit opinion provide some support. Promoter reclassification requests could signal reduced promoter holding in future.